{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:31:16Z","timestamp":1775266276003,"version":"3.50.1"},"reference-count":254,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Ministry of Education and Science | Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2023.03179.BD"],"award-info":[{"award-number":["2023.03179.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Ministry of Education and Science | Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/138674\/2018"],"award-info":[{"award-number":["SFRH\/BD\/138674\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Chem"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>PROteolysis-Targeting Chimeras (PROTACs) are an emerging class of molecules capable of inducing a forced approximation between a protein of interest (POI) and an E3 ligase enzyme (e.g., Cereblon), leading to the degradation of the POI by the cell\u2019s own machinery. Although in early stages of development, PROTACs\u2019 unique mechanisms of action offer a novel therapeutic strategy, which has attracted growing interest worldwide. Cereblon-based PROTACs are the most studied class of PROTACs and have been actively researched in recent years for the treatment of different diseases, from cancer to neurological disorders, with some of them already in clinical trials. In this review, we provide a comprehensive and critical analysis covering the recent advances, potential challenges and future prospects regarding the design and synthesis, as well as pre- and clinical evaluation of cereblon-based PROTACs. By integrating insights from drug discovery and development, a broad yet in-depth discussion is given to guide future research on cereblon-based PROTACs.<\/jats:p>","DOI":"10.1038\/s42004-025-01598-9","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T12:44:21Z","timestamp":1753793061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7193-4025","authenticated-orcid":false,"given":"Andr\u00e9 T. S.","family":"Vicente","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5791-6528","authenticated-orcid":false,"given":"Sara P. S. P.","family":"Moura","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0779-6083","authenticated-orcid":false,"given":"Jorge A. R.","family":"Salvador","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"key":"1598_CR1","doi-asserted-by":"publisher","first-page":"115765","DOI":"10.1016\/j.ejmech.2023.115765","volume":"260","author":"R Amirian","year":"2023","unstructured":"Amirian, R. et al. Targeted protein modification as a paradigm shift in drug discovery. Eur. J. Med. Chem. 260, 115765 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/wsbm.1185","volume":"4","author":"S Prabakaran","year":"2012","unstructured":"Prabakaran, S., Lippens, G., Steen, H. & Gunawardena, J. Post\u2010translational modification: nature\u2019s escape from genetic imprisonment and the basis for dynamic information encoding. WIREs Syst. Biol. Med. 4, 565\u2013583 (2012).","journal-title":"WIREs Syst. Biol. Med."},{"key":"1598_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35795-8","volume":"14","author":"JM Lee","year":"2023","unstructured":"Lee, J. M., Hammar\u00e9n, H. M., Savitski, M. M. & Baek, S. H. Control of protein stability by post-translational modifications. Nat. Commun. 14, 201 (2023).","journal-title":"Nat. Commun."},{"key":"1598_CR4","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00424-021-02624-0","volume":"473","author":"HK Kim","year":"2021","unstructured":"Kim, H. K. et al. Cereblon: promise and challenges for combating human diseases. Pfl\u00fcgers Arch. Eur. J. Physiol. 473, 1695\u20131711 (2021). This article highlights the critical role of cereblon in disease treatment, emphasizing its therapeutic potential in cancer and other disorders, while addressing the challenges in optimizing drug efficacy and safety.","journal-title":"Pfl\u00fcgers Arch. Eur. J. Physiol."},{"key":"1598_CR5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.aax3769","volume":"366","author":"C Pohl","year":"2019","unstructured":"Pohl, C. & Dikic, I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science 366, 818\u2013822 (2019).","journal-title":"Science"},{"key":"1598_CR6","doi-asserted-by":"crossref","unstructured":"Wang, Y. & Le, W. D. Autophagy and ubiquitin-proteasome system. In Autophagy: Biology and Diseases. Adv. Exp. Med. Biol. 1206, 417\u2013441 (2019).","DOI":"10.1007\/978-981-15-0602-4_25"},{"key":"1598_CR7","doi-asserted-by":"publisher","first-page":"108525","DOI":"10.1016\/j.pharmthera.2023.108525","volume":"250","author":"D Choudhary","year":"2023","unstructured":"Choudhary, D. et al. Target protein degradation by protacs: a budding cancer treatment strategy. Pharmacol. Ther. 250, 108525 (2023).","journal-title":"Pharmacol. Ther."},{"key":"1598_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","volume":"181","author":"GM Burslem","year":"2020","unstructured":"Burslem, G. M. & Crews, C. M. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell 181, 102\u2013114 (2020).","journal-title":"Cell"},{"key":"1598_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.tcb.2013.12.003","volume":"24","author":"G Kleiger","year":"2014","unstructured":"Kleiger, G. & Mayor, T. Perilous journey: a tour of the ubiquitin\u2013proteasome system. Trends Cell Biol. 24, 352\u2013359 (2014). Explores the complexities of the ubiquitin-proteasome system, crucial for regulating protein degradation. It emphasizes its significance in cellular function, disease mechanisms, and potential therapeutic targets.","journal-title":"Trends Cell Biol."},{"key":"1598_CR10","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","volume":"43","author":"J Park","year":"2020","unstructured":"Park, J., Cho, J. & Song, E. J. Ubiquitin\u2013proteasome system (UPS) as a target for anticancer treatment. Arch. Pharm. Res. 43, 1144\u20131161 (2020).","journal-title":"Arch. Pharm. Res."},{"key":"1598_CR11","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.3390\/cells12141846","volume":"12","author":"Y Kim","year":"2023","unstructured":"Kim, Y., Kim, E.-K., Chey, Y., Song, M.-J. & Jang, H. H. Targeted protein degradation: principles and applications of the proteasome. Cells 12, 1846 (2023).","journal-title":"Cells"},{"key":"1598_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.tibs.2017.09.002","volume":"42","author":"YT Kwon","year":"2017","unstructured":"Kwon, Y. T. & Ciechanover, A. The ubiquitin code in the ubiquitin-proteasome system and autophagy. Trends Biochem. Sci. 42, 873\u2013886 (2017).","journal-title":"Trends Biochem. Sci."},{"key":"1598_CR13","doi-asserted-by":"publisher","first-page":"103395","DOI":"10.1016\/j.drudis.2022.103395","volume":"28","author":"N Guedeney","year":"2023","unstructured":"Guedeney, N., Cornu, M., Schwalen, F., Kieffer, C. & Voisin-Chiret, A. S. PROTAC technology: a new drug design for chemical biology with many challenges in drug discovery. Drug Discov. Today 28, 103395 (2023).","journal-title":"Drug Discov. Today"},{"key":"1598_CR14","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/med.21502","volume":"38","author":"R Mishra","year":"2018","unstructured":"Mishra, R., Upadhyay, A., Prajapati, V. K. & Mishra, A. Proteasome\u2010mediated proteostasis: novel medicinal and pharmacological strategies for diseases. Med. Res. Rev. 38, 1916\u20131973 (2018).","journal-title":"Med. Res. Rev."},{"key":"1598_CR15","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nrd2056","volume":"5","author":"G Nalepa","year":"2006","unstructured":"Nalepa, G., Rolfe, M. & Harper, J. W. Drug discovery in the ubiquitin\u2013proteasome system. Nat. Rev. Drug Discov. 5, 596\u2013613 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1598_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41418-020-00703-w","volume":"28","author":"RB Damgaard","year":"2021","unstructured":"Damgaard, R. B. The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities. Cell Death Differ. 28, 423\u2013426 (2021).","journal-title":"Cell Death Differ."},{"key":"1598_CR17","doi-asserted-by":"publisher","first-page":"107264","DOI":"10.1016\/j.jbc.2024.107264","volume":"300","author":"Y Chen","year":"2024","unstructured":"Chen, Y., Xue, H. & Jin, J. Applications of protein ubiquitylation and deubiquitylation in drug discovery. J. Biol. Chem. 300, 107264 (2024).","journal-title":"J. Biol. Chem."},{"key":"1598_CR18","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/med.21877","volume":"42","author":"S He","year":"2022","unstructured":"He, S., Dong, G., Cheng, J., Wu, Y. & Sheng, C. Strategies for designing proteolysis targeting chimaeras (PROTACs). Med. Res. Rev. 42, 1280\u20131342 (2022).","journal-title":"Med. Res. Rev."},{"key":"1598_CR19","doi-asserted-by":"publisher","first-page":"8554","DOI":"10.1073\/pnas.141230798","volume":"98","author":"KM Sakamoto","year":"2001","unstructured":"Sakamoto, K. M. et al. Protacs: chimeric molecules that target proteins to the Skp1\u2013Cullin\u2013F box complex for ubiquitination and degradation. Proc. Natl. Acad. Sci. USA 98, 8554\u20138559 (2001). The first to report on the development of PROTACs, marking a major innovation in the field by introducing chimeric molecules designed to induce targeted protein degradation through the Skp1\u2013Cullin\u2013F box complex.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1598_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.semcancer.2020.02.006","volume":"67","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. PROTACs: a novel strategy for cancer therapy. Semin. Cancer Biol. 67, 171\u2013179 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"1598_CR21","doi-asserted-by":"publisher","first-page":"115444","DOI":"10.1016\/j.ejmech.2023.115444","volume":"256","author":"D Mi","year":"2023","unstructured":"Mi, D., Li, Y., Gu, H., Li, Y. & Chen, Y. Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design. Eur. J. Med. Chem. 256, 115444 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01707-5","volume":"22","author":"JM Kelm","year":"2023","unstructured":"Kelm, J. M. et al. PROTAC\u2019ing oncoproteins: targeted protein degradation for cancer therapy. Mol. Cancer 22, 62 (2023).","journal-title":"Mol. Cancer"},{"key":"1598_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cbf.3369","volume":"37","author":"Y Zou","year":"2019","unstructured":"Zou, Y., Ma, D. & Wang, Y. The PROTAC technology in drug development. Cell Biochem. Funct. 37, 21\u201330 (2019).","journal-title":"Cell Biochem. Funct."},{"key":"1598_CR24","doi-asserted-by":"publisher","first-page":"216065","DOI":"10.1016\/j.canlet.2023.216065","volume":"556","author":"SD Kaur","year":"2023","unstructured":"Kaur, S. D., Bedi, N., Kumar, D. & Kapoor, D. N. PROTACs: promising approach for anticancer therapy. Cancer Lett. 556, 216065 (2023).","journal-title":"Cancer Lett."},{"key":"1598_CR25","doi-asserted-by":"publisher","first-page":"112981","DOI":"10.1016\/j.ejmech.2020.112981","volume":"210","author":"S Zeng","year":"2021","unstructured":"Zeng, S. et al. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges. Eur. J. Med. Chem. 210, 112981 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR26","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41568-021-00365-x","volume":"21","author":"B Dale","year":"2021","unstructured":"Dale, B. et al. Advancing targeted protein degradation for cancer therapy. Nat. Rev. Cancer 21, 638\u2013654 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1598_CR27","doi-asserted-by":"publisher","first-page":"115037","DOI":"10.1016\/j.ejmech.2022.115037","volume":"247","author":"Y-W Wang","year":"2023","unstructured":"Wang, Y.-W. et al. PROTACS: a technology with a gold rush-like atmosphere. Eur. J. Med. Chem. 247, 115037 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR28","doi-asserted-by":"publisher","first-page":"117212","DOI":"10.1016\/j.ejmech.2024.117212","volume":"284","author":"B Cheng","year":"2025","unstructured":"Cheng, B. et al. Recent advances in developing targeted protein degraders. Eur. J. Med. Chem. 284, 117212 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR29","doi-asserted-by":"publisher","first-page":"116166","DOI":"10.1016\/j.ejmech.2024.116166","volume":"267","author":"X Wang","year":"2024","unstructured":"Wang, X. et al. Annual review of PROTAC degraders as anticancer agents in 2022. Eur. J. Med. Chem. 267, 116166 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR30","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1021\/acschembio.0c00348","volume":"15","author":"B Tong","year":"2020","unstructured":"Tong, B. et al. A nimbolide-based kinase degrader preferentially degrades oncogenic BCR-ABL. ACS Chem. Biol. 15, 1788\u20131794 (2020).","journal-title":"ACS Chem. Biol."},{"key":"1598_CR31","doi-asserted-by":"publisher","first-page":"156001","DOI":"10.1016\/j.prp.2025.156001","volume":"270","author":"MS Hussain","year":"2025","unstructured":"Hussain, M. S. et al. Exploiting E3 ligases for lung cancer therapy: the promise of DCAF-PROTACs. Pathol. Res. Pract. 270, 156001 (2025).","journal-title":"Pathol. Res. Pract."},{"key":"1598_CR32","doi-asserted-by":"publisher","first-page":"102783","DOI":"10.1016\/j.redox.2023.102783","volume":"64","author":"SY Park","year":"2023","unstructured":"Park, S. Y. et al. Development of KEAP1-targeting PROTAC and its antioxidant properties: in vitro and in vivo. Redox Biol. 64, 102783 (2023).","journal-title":"Redox Biol."},{"key":"1598_CR33","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3390\/pharmaceutics15030812","volume":"15","author":"M Cie\u015blak","year":"2023","unstructured":"Cie\u015blak, M. & S\u0142owianek, M. Cereblon-recruiting PROTACs: will new drugs have to face old challenges? Pharmaceutics 15, 812 (2023).","journal-title":"Pharmaceutics"},{"key":"1598_CR34","doi-asserted-by":"publisher","first-page":"113749","DOI":"10.1016\/j.ejmech.2021.113749","volume":"225","author":"C Wang","year":"2021","unstructured":"Wang, C., Zhang, Y., Wu, Y. & Xing, D. Developments of CRBN-based PROTACs as potential therapeutic agents. Eur. J. Med. Chem. 225, 113749 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/mco2.575","volume":"5","author":"ATS Vicente","year":"2024","unstructured":"Vicente, A. T. S. & Salvador, J. A. R. PROteolysis-Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives. MedComm 5, 1\u201341 (2024).","journal-title":"MedComm"},{"key":"1598_CR36","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1212\/01.WNL.0000146196.01316.A2","volume":"63","author":"JJ Higgins","year":"2004","unstructured":"Higgins, J. J., Pucilowska, J., Lombardi, R. Q. & Rooney, J. P. A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 63, 1927\u20131931 (2004).","journal-title":"Neurology"},{"key":"1598_CR37","doi-asserted-by":"publisher","first-page":"167457","DOI":"10.1016\/j.jmb.2022.167457","volume":"434","author":"L Zhou","year":"2022","unstructured":"Zhou, L. & Xu, G. The ubiquitination-dependent and -independent functions of cereblon in cancer and neurological diseases. J. Mol. Biol. 434, 167457 (2022).","journal-title":"J. Mol. Biol."},{"key":"1598_CR38","doi-asserted-by":"publisher","first-page":"100994","DOI":"10.1016\/j.blre.2022.100994","volume":"57","author":"O Fuchs","year":"2023","unstructured":"Fuchs, O. Targeting cereblon in hematologic malignancies. Blood Rev. 57, 100994 (2023).","journal-title":"Blood Rev."},{"key":"1598_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.bbcan.2018.11.007","volume":"1871","author":"J Cheng","year":"2019","unstructured":"Cheng, J. et al. The emerging role for Cullin 4 family of E3 ligases in tumorigenesis. Biochim. Biophys. Acta Rev. Cancer 1871, 138\u2013159 (2019).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"1598_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.semcancer.2020.03.007","volume":"67","author":"KM Nguyen","year":"2020","unstructured":"Nguyen, K. M. & Busino, L. Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy. Semin. Cancer Biol. 67, 53\u201360 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"1598_CR41","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.biocel.2011.09.001","volume":"43","author":"B Iovine","year":"2011","unstructured":"Iovine, B., Iannella, M. L. & Bevilacqua, M. A. Damage-specific DNA binding protein 1 (DDB1): a protein with a wide range of functions. Int. J. Biochem. Cell Biol. 43, 1664\u20131667 (2011).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"1598_CR42","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00424-016-1854-1","volume":"468","author":"HK Kim","year":"2016","unstructured":"Kim, H. K. et al. Cereblon in health and disease. Pfl\u00fcgers Arch. Eur. J. Physiol. 468, 1299\u20131309 (2016).","journal-title":"Pfl\u00fcgers Arch. Eur. J. Physiol."},{"key":"1598_CR43","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/jb\/mvad113","volume":"175","author":"T Ito","year":"2024","unstructured":"Ito, T. Protein degraders\u2014from thalidomide to new PROTACs. J. Biochem 175, 507\u2013519 (2024).","journal-title":"J. Biochem"},{"key":"1598_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxsci\/kfr088","volume":"122","author":"JH Kim","year":"2011","unstructured":"Kim, J. H. & Scialli, A. R. Thalidomide: the tragedy of birth defects and the effective treatment of disease. Toxicol. Sci. 122, 1\u20136 (2011).","journal-title":"Toxicol. Sci."},{"key":"1598_CR45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/bdrc.21096","volume":"105","author":"N Vargesson","year":"2015","unstructured":"Vargesson, N. Thalidomide\u2010induced teratogenesis: history and mechanisms. Birth Defects Res. C Embryo Today Rev. 105, 140\u2013156 (2015).","journal-title":"Birth Defects Res. C Embryo Today Rev."},{"key":"1598_CR46","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345\u20131350 (2010).","journal-title":"Science"},{"key":"1598_CR47","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326\u20132335 (2012).","journal-title":"Leukemia"},{"key":"1598_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins. Science 343, 305\u2013309 (2014).","journal-title":"Science"},{"key":"1598_CR49","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kr\u00f6nke","year":"2014","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301\u2013305 (2014).","journal-title":"Science"},{"key":"1598_CR50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.hoc.2024.01.001","volume":"38","author":"H Lee","year":"2024","unstructured":"Lee, H., Neri, P. & Bahlis, N. J. Cereblon-targeting ligase degraders in myeloma. Hematol. Oncol. Clin. North Am. 38, 305\u2013319 (2024).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"1598_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13527","volume":"512","author":"ES Fischer","year":"2014","unstructured":"Fischer, E. S. et al. Structure of the DDB1\u2013CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49\u201353 (2014).","journal-title":"Nature"},{"key":"1598_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19202-7","volume":"8","author":"T Mori","year":"2018","unstructured":"Mori, T. et al. Structural basis of thalidomide enantiomer binding to cereblon. Sci. Rep. 8, 1294 (2018).","journal-title":"Sci. Rep."},{"key":"1598_CR53","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/13543776.2022.1999415","volume":"32","author":"A Kazantsev","year":"2022","unstructured":"Kazantsev, A. & Krasavin, M. Ligands for cereblon: 2017\u20132021 patent overview. Expert Opin. Ther. Pat. 32, 171\u2013190 (2022). This article provides an overview of patents related to cereblon ligands from 2017 to 2021.","journal-title":"Expert Opin. Ther. Pat."},{"key":"1598_CR54","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.3390\/molecules26092525","volume":"26","author":"GY Kim","year":"2021","unstructured":"Kim, G. Y. et al. Chemical degradation of androgen receptor (AR) using bicalutamide analog\u2013thalidomide PROTACs. Molecules 26, 2525 (2021).","journal-title":"Molecules"},{"key":"1598_CR55","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41589-020-00652-y","volume":"16","author":"B Adhikari","year":"2020","unstructured":"Adhikari, B. et al. PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase. Nat. Chem. Biol. 16, 1179\u20131188 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"1598_CR56","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1021\/acsmedchemlett.0c00605","volume":"12","author":"H Yokoo","year":"2021","unstructured":"Yokoo, H. et al. Development of a hematopoietic prostaglandin D synthase-degradation inducer. ACS Med. Chem. Lett. 12, 236\u2013241 (2021).","journal-title":"ACS Med. Chem. Lett."},{"key":"1598_CR57","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1002\/cmdc.202000872","volume":"16","author":"M Konstantinidou","year":"2021","unstructured":"Konstantinidou, M. et al. The tale of proteolysis targeting chimeras (PROTACs) for Leucine\u2010Rich Repeat Kinase 2 (LRRK2). ChemMedChem 16, 959\u2013965 (2021).","journal-title":"ChemMedChem"},{"key":"1598_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11429-w","volume":"10","author":"M de Wispelaere","year":"2019","unstructured":"de Wispelaere, M. et al. Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat. Commun. 10, 3468 (2019).","journal-title":"Nat. Commun."},{"key":"1598_CR59","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1177\/2472555220965528","volume":"26","author":"T Ishida","year":"2021","unstructured":"Ishida, T. & Ciulli, A. E3 ligase ligands for PROTACs: how they were found and how to discover new ones. SLAS Discov. 26, 484\u2013502 (2021).","journal-title":"SLAS Discov."},{"key":"1598_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4155\/fmc-2021-0208","volume":"14","author":"V Poongavanam","year":"2022","unstructured":"Poongavanam, V. & Kihlberg, J. PROTAC cell permeability and oral bioavailability: a journey into uncharted territory. Future Med. Chem. 14, 123\u2013126 (2022).","journal-title":"Future Med. Chem."},{"key":"1598_CR61","doi-asserted-by":"crossref","unstructured":"Bricelj, A., Steinebach, C., Kuchta, R., G\u00fctschow, M. & Sosi\u010d, I. E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points. Front. Chem. 9, 707317 (2021).","DOI":"10.3389\/fchem.2021.707317"},{"key":"1598_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42233-2","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Expanding PROTACtable genome universe of E3 ligases. Nat. Commun. 14, 6509 (2023).","journal-title":"Nat. Commun."},{"key":"1598_CR63","doi-asserted-by":"publisher","first-page":"117334","DOI":"10.1016\/j.bmc.2023.117334","volume":"88\u201389","author":"NA Zografou-Barredo","year":"2023","unstructured":"Zografou-Barredo, N. A., Hallatt, A. J., Goujon-Ricci, J. & Cano, C. A beginner\u2019s guide to current synthetic linker strategies towards VHL-recruiting PROTACs. Bioorg. Med. Chem. 88\u201389, 117334 (2023).","journal-title":"Bioorg. Med. Chem."},{"key":"1598_CR64","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1039\/D2CS00148A","volume":"51","author":"I Sosi\u010d","year":"2022","unstructured":"Sosi\u010d, I., Bricelj, A. & Steinebach, C. E3 ligase ligand chemistries: from building blocks to protein degraders. Chem. Soc. Rev. 51, 3487\u20133534 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"1598_CR65","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/13543776.2023.2240025","volume":"33","author":"ATS Vicente","year":"2023","unstructured":"Vicente, A. T. S. & Salvador, J. A. R. Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia\u2014a patent review. Expert Opin. Ther. Pat. 33, 397\u2013420 (2023).","journal-title":"Expert Opin. Ther. Pat."},{"key":"1598_CR66","doi-asserted-by":"publisher","first-page":"114838","DOI":"10.1016\/j.ejmech.2022.114838","volume":"244","author":"D Li","year":"2022","unstructured":"Li, D., Yu, D., Li, Y. & Yang, R. A bibliometric analysis of PROTAC from 2001 to 2021. Eur. J. Med. Chem. 244, 114838 (2022). A bibliometric analysis of PROTAC research from 2001 to 2021, shedding light on the growth, trends, and key advancements in the field.","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR67","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ejmech.2018.03.071","volume":"151","author":"C Zhang","year":"2018","unstructured":"Zhang, C. et al. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). Eur. J. Med. Chem. 151, 304\u2013314 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR68","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1021\/acs.jmedchem.7b01655","volume":"61","author":"CE Powell","year":"2018","unstructured":"Powell, C. E. et al. Chemically induced degradation of Anaplastic Lymphoma Kinase (ALK). J. Med. Chem. 61, 4249\u20134255 (2018).","journal-title":"J. Med. Chem."},{"key":"1598_CR69","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nchembio.2538","volume":"14","author":"CM Olson","year":"2018","unstructured":"Olson, C. M. et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat. Chem. Biol. 14, 163\u2013170 (2018). This article compares selective CDK9 inhibition and degradation, emphasizing that while inhibition temporarily halts CDK9 activity, degradation offers a more persistent and potentially more effective therapeutic approach by eliminating the target protein entirely.","journal-title":"Nat. Chem. Biol."},{"key":"1598_CR70","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1039\/C9MD00185A","volume":"10","author":"C Steinebach","year":"2019","unstructured":"Steinebach, C. et al. A MedChem toolbox for cereblon-directed PROTACs. Medchemcomm 10, 1037\u20131041 (2019).","journal-title":"Medchemcomm"},{"key":"1598_CR71","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1039\/D0SC05442A","volume":"12","author":"DK Brownsey","year":"2021","unstructured":"Brownsey, D. K., Rowley, B. C., Gorobets, E., Gelfand, B. S. & Derksen, D. J. Rapid synthesis of pomalidomide-conjugates for the development of protein degrader libraries. Chem. Sci. 12, 4519\u20134525 (2021).","journal-title":"Chem. Sci."},{"key":"1598_CR72","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/s41589-020-0609-7","volume":"16","author":"G Posternak","year":"2020","unstructured":"Posternak, G. et al. Functional characterization of a PROTAC directed against BRAF mutant V600E. Nat. Chem. Biol. 16, 1170\u20131178 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"1598_CR73","doi-asserted-by":"publisher","first-page":"14562","DOI":"10.1021\/acs.jmedchem.0c01342","volume":"63","author":"L Chen","year":"2020","unstructured":"Chen, L. et al. Discovery of first-in-class potent and selective tropomyosin receptor kinase degraders. J. Med. Chem. 63, 14562\u201314575 (2020).","journal-title":"J. Med. Chem."},{"key":"1598_CR74","doi-asserted-by":"publisher","first-page":"117867","DOI":"10.1016\/j.bmc.2024.117867","volume":"111","author":"F Zhang","year":"2024","unstructured":"Zhang, F. et al. Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1\/PD-L1 interaction. Bioorg. Med. Chem. 111, 117867 (2024).","journal-title":"Bioorg. Med. Chem."},{"key":"1598_CR75","doi-asserted-by":"publisher","first-page":"117134","DOI":"10.1016\/j.bmc.2022.117134","volume":"78","author":"M Ding","year":"2023","unstructured":"Ding, M. et al. Design, synthesis, and biological evaluation of BRD4 degraders. Bioorg. Med. Chem. 78, 117134 (2023).","journal-title":"Bioorg. Med. Chem."},{"key":"1598_CR76","doi-asserted-by":"publisher","first-page":"117352","DOI":"10.1016\/j.bmc.2023.117352","volume":"90","author":"M Cai","year":"2023","unstructured":"Cai, M. et al. Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4. Bioorg. Med. Chem. 90, 117352 (2023).","journal-title":"Bioorg. Med. Chem."},{"key":"1598_CR77","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1021\/acsmedchemlett.3c00498","volume":"15","author":"D Grifagni","year":"2024","unstructured":"Grifagni, D. et al. Development of a GC-376 based peptidomimetic PROTAC as a degrader of 3-chymotrypsin-like protease of SARS-CoV-2. ACS Med. Chem. Lett. 15, 250\u2013257 (2024).","journal-title":"ACS Med. Chem. Lett."},{"key":"1598_CR78","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1080\/00397911.2016.1189574","volume":"46","author":"D Huang","year":"2016","unstructured":"Huang, D. et al. New synthesis route for the preparation of pomalidomide. Synth. Commun. 46, 1343\u20131348 (2016).","journal-title":"Synth. Commun."},{"key":"1598_CR79","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.bmcl.2019.03.035","volume":"29","author":"S Rana","year":"2019","unstructured":"Rana, S. et al. Selective degradation of CDK6 by a palbociclib based PROTAC. Bioorg. Med. Chem. Lett. 29, 1375\u20131379 (2019).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1598_CR80","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1021\/acschembio.8b00693","volume":"13","author":"C Steinebach","year":"2018","unstructured":"Steinebach, C. et al. Homo-PROTACs for the chemical knockdown of cereblon. ACS Chem. Biol. 13, 2771\u20132782 (2018). Explores the use of Homo-PROTACs for the chemical knockdown of cereblon, offering a novel strategy to selectively degrade cereblon and potentially enhance therapeutic approaches for diseases associated with its dysfunction.","journal-title":"ACS Chem. Biol."},{"key":"1598_CR81","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.bioorg.2018.09.005","volume":"81","author":"H Chen","year":"2018","unstructured":"Chen, H., Chen, F., Liu, N., Wang, X. & Gou, S. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin\u2013proteasome pathway. Bioorg. Chem. 81, 536\u2013544 (2018).","journal-title":"Bioorg. Chem."},{"key":"1598_CR82","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/anie.201507634","volume":"55","author":"AC Lai","year":"2016","unstructured":"Lai, A. C. et al. Modular PROTAC design for the degradation of oncogenic BCR\u2010ABL. Angew. Chem. Int. Ed. 55, 807\u2013810 (2016).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1598_CR83","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.bioorg.2018.08.028","volume":"81","author":"J Bian","year":"2018","unstructured":"Bian, J. et al. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity. Bioorg. Chem. 81, 373\u2013381 (2018).","journal-title":"Bioorg. Chem."},{"key":"1598_CR84","doi-asserted-by":"crossref","unstructured":"Liu, H. et al. Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor. Eur. J. Med. Chem. 244, 114810 (2022). The discovery of novel potent BCR-ABL degraders, created by conjugating an allosteric inhibitor.","DOI":"10.1016\/j.ejmech.2022.114810"},{"key":"1598_CR85","doi-asserted-by":"publisher","first-page":"115690","DOI":"10.1016\/j.ejmech.2023.115690","volume":"260","author":"Q Jiang","year":"2023","unstructured":"Jiang, Q. et al. Discovery of X10g as a selective PROTAC degrader of Hsp90\u03b1 protein for treating breast cancer. Eur. J. Med. Chem. 260, 115690 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR86","doi-asserted-by":"publisher","first-page":"16290","DOI":"10.3390\/ijms242216290","volume":"24","author":"P Pan","year":"2023","unstructured":"Pan, P. et al. Design, synthesis, and antitumor activity evaluation of proteolysis-targeting chimeras as degraders of extracellular signal-regulated kinases 1\/2. Int. J. Mol. Sci. 24, 16290 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1598_CR87","doi-asserted-by":"publisher","first-page":"7569","DOI":"10.1021\/acs.jmedchem.4c00356","volume":"67","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Discovery of selective proteolysis-targeting chimera degraders targeting PTP1B as long-term hypoglycemic agents. J. Med. Chem. 67, 7569\u20137584 (2024). One of the first examples of PROTACs being used for diabetes treatment, specifically targeting PTP1B as a promising strategy for developing long-term hypoglycemic agents.","journal-title":"J. Med. Chem."},{"key":"1598_CR88","doi-asserted-by":"publisher","first-page":"11354","DOI":"10.1021\/acs.jmedchem.4c00965","volume":"67","author":"H He","year":"2024","unstructured":"He, H. et al. Development of degraders of cyclin-dependent kinases 4 and 6 based on rational drug design. J. Med. Chem. 67, 11354\u201311364 (2024).","journal-title":"J. Med. Chem."},{"key":"1598_CR89","doi-asserted-by":"publisher","first-page":"17259","DOI":"10.1021\/acs.jmedchem.4c01130","volume":"67","author":"G Wilms","year":"2024","unstructured":"Wilms, G. et al. Discovery and functional characterization of a potent, selective, and metabolically stable PROTAC of the protein kinases DYRK1A and DYRK1B. J. Med. Chem. 67, 17259\u201317289 (2024).","journal-title":"J. Med. Chem."},{"key":"1598_CR90","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","volume":"25","author":"H-T Huang","year":"2018","unstructured":"Huang, H.-T. et al. A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader. Cell Chem. Biol. 25, 88\u201399.e6 (2018).","journal-title":"Cell Chem. Biol."},{"key":"1598_CR91","doi-asserted-by":"publisher","first-page":"106556","DOI":"10.1016\/j.bioorg.2023.106556","volume":"136","author":"L Gong","year":"2023","unstructured":"Gong, L. et al. Discovery of a miniaturized PROTAC with potent activity and high selectivity. Bioorg. Chem. 136, 106556 (2023).","journal-title":"Bioorg. Chem."},{"key":"1598_CR92","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1021\/acsmedchemlett.1c00368","volume":"12","author":"A Bricelj","year":"2021","unstructured":"Bricelj, A. et al. Influence of linker attachment points on the stability and neosubstrate degradation of cereblon ligands. ACS Med. Chem. Lett. 12, 1733\u20131738 (2021).","journal-title":"ACS Med. Chem. Lett."},{"key":"1598_CR93","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1021\/acs.jmedchem.7b01406","volume":"61","author":"NEA Chessum","year":"2018","unstructured":"Chessum, N. E. A. et al. Demonstrating in-cell target engagement using a pirin protein degradation probe (CCT367766). J. Med. Chem. 61, 918\u2013933 (2018).","journal-title":"J. Med. Chem."},{"key":"1598_CR94","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1039\/D0SC00167H","volume":"11","author":"C Steinebach","year":"2020","unstructured":"Steinebach, C. et al. Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. Chem. Sci. 11, 3474\u20133486 (2020).","journal-title":"Chem. Sci."},{"key":"1598_CR95","doi-asserted-by":"publisher","first-page":"116827","DOI":"10.1016\/j.ejmech.2024.116827","volume":"279","author":"H Zhou","year":"2024","unstructured":"Zhou, H. et al. Discovery of orally bioavailable ALK PROTACs based ceritinib against ALK positive cancers. Eur. J. Med. Chem. 279, 116827 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR96","doi-asserted-by":"publisher","first-page":"115774","DOI":"10.1016\/j.ejmech.2023.115774","volume":"260","author":"T Wu","year":"2023","unstructured":"Wu, T. et al. Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy. Eur. J. Med. Chem. 260, 115774 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR97","doi-asserted-by":"publisher","first-page":"107016","DOI":"10.1016\/j.bioorg.2023.107016","volume":"143","author":"S Zeng","year":"2024","unstructured":"Zeng, S. et al. Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling. Bioorg. Chem. 143, 107016 (2024).","journal-title":"Bioorg. Chem."},{"key":"1598_CR98","doi-asserted-by":"publisher","first-page":"115403","DOI":"10.1016\/j.ejmech.2023.115403","volume":"255","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy. Eur. J. Med. Chem. 255, 115403 (2023). A novel BTK PROTACs with enhanced metabolic stability, achieved through a linker rigidification strategy.","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR99","doi-asserted-by":"publisher","first-page":"107923","DOI":"10.1016\/j.cclet.2022.107923","volume":"34","author":"A Chen","year":"2023","unstructured":"Chen, A. et al. Identification of highly efficacious PROTACs targeting BRD4 against acute myeloid leukemia: Design, synthesis, and biological evaluations. Chin. Chem. Lett. 34, 107923 (2023).","journal-title":"Chin. Chem. Lett."},{"key":"1598_CR100","doi-asserted-by":"publisher","first-page":"18247","DOI":"10.1021\/acs.jmedchem.4c01596","volume":"67","author":"L Zhou","year":"2024","unstructured":"Zhou, L. et al. Discovery of ZLC491 as a potent, selective, and orally bioavailable CDK12\/13 PROTAC degrader. J. Med. Chem. 67, 18247\u201318264 (2024).","journal-title":"J. Med. Chem."},{"key":"1598_CR101","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1021\/ol034906w","volume":"5","author":"SM Capitosti","year":"2003","unstructured":"Capitosti, S. M., Hansen, T. P. & Brown, M. L. Facile synthesis of an azido-labeled thalidomide analogue. Org. Lett. 5, 2865\u20132867 (2003).","journal-title":"Org. Lett."},{"key":"1598_CR102","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","volume":"57","author":"AD Buhimschi","year":"2018","unstructured":"Buhimschi, A. D. et al. Targeting the C481S ibrutinib-resistance mutation in Bruton\u2019s tyrosine kinase using PROTAC-mediated degradation. Biochemistry 57, 3564\u20133575 (2018).","journal-title":"Biochemistry"},{"key":"1598_CR103","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00277-023-05545-3","volume":"103","author":"CJ Lap","year":"2024","unstructured":"Lap, C. J., Abrahim, M. S. & Nassereddine, S. Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia. Ann. Hematol. 103, 2215\u20132229 (2024).","journal-title":"Ann. Hematol."},{"key":"1598_CR104","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11912-023-01389-2","volume":"25","author":"R Bystrom","year":"2023","unstructured":"Bystrom, R. & Levis, M. J. An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape. Curr. Oncol. Rep. 25, 369\u2013378 (2023).","journal-title":"Curr. Oncol. Rep."},{"key":"1598_CR105","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.3390\/jcm12206429","volume":"12","author":"C Negotei","year":"2023","unstructured":"Negotei, C. et al. A review of FLT3 kinase inhibitors in AML. J. Clin. Med. 12, 6429 (2023).","journal-title":"J. Clin. Med."},{"key":"1598_CR106","doi-asserted-by":"publisher","first-page":"7197","DOI":"10.1021\/acs.jmedchem.4c00051","volume":"67","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. Discovery of a novel orally bioavailable FLT3-PROTAC degrader for efficient treatment of acute myeloid leukemia and overcoming resistance of FLT3 inhibitors. J. Med. Chem. 67, 7197\u20137223 (2024).","journal-title":"J. Med. Chem."},{"key":"1598_CR107","doi-asserted-by":"publisher","first-page":"107477","DOI":"10.1016\/j.bioorg.2024.107477","volume":"149","author":"L Ye","year":"2024","unstructured":"Ye, L. et al. Discovery of a potent Gilteritinib-based FLT3-PROTAC degrader for the treatment of Acute myeloid leukemia. Bioorg. Chem. 149, 107477 (2024).","journal-title":"Bioorg. Chem."},{"key":"1598_CR108","doi-asserted-by":"publisher","first-page":"116539","DOI":"10.1016\/j.ejmech.2024.116539","volume":"275","author":"M Wu","year":"2024","unstructured":"Wu, M. et al. Discovery of a potent CDKs\/FLT3 PROTAC with enhanced differentiation and proliferation inhibition for AML. Eur. J. Med. Chem. 275, 116539 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/advs.202400398","volume":"11","author":"S Lee","year":"2024","unstructured":"Lee, S. et al. UBX\u2010390: a novel androgen receptor degrader for therapeutic intervention in prostate cancer. Adv. Sci. 11, 1\u201313 (2024).","journal-title":"Adv. Sci."},{"key":"1598_CR110","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1021\/acs.jmedchem.6b01816","volume":"61","author":"B Zhou","year":"2018","unstructured":"Zhou, B. et al. Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J. Med. Chem. 61, 462\u2013481 (2018).","journal-title":"J. Med. Chem."},{"key":"1598_CR111","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1002\/anie.201901336","volume":"58","author":"B Jiang","year":"2019","unstructured":"Jiang, B. et al. Development of dual and selective degraders of cyclin\u2010dependent kinases 4 and 6. Angew. Chem. Int. Ed. 58, 6321\u20136326 (2019).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1598_CR112","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1021\/acs.jmedchem.9b00455","volume":"62","author":"JW Papatzimas","year":"2019","unstructured":"Papatzimas, J. W. et al. From inhibition to degradation: targeting the antiapoptotic protein myeloid cell leukemia 1 (MCL1). J. Med. Chem. 62, 5522\u20135540 (2019).","journal-title":"J. Med. Chem."},{"key":"1598_CR113","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1021\/acsmedchemlett.0c00194","volume":"11","author":"DE Scott","year":"2020","unstructured":"Scott, D. E. et al. Systematic investigation of the permeability of androgen receptor PROTACs. ACS Med. Chem. Lett. 11, 1539\u20131547 (2020).","journal-title":"ACS Med. Chem. Lett."},{"key":"1598_CR114","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1021\/acschembio.8b00698","volume":"13","author":"W McCoull","year":"2018","unstructured":"McCoull, W. et al. Development of a novel B-cell lymphoma 6 (BCL6) PROTAC to provide insight into small molecule targeting of BCL6. ACS Chem. Biol. 13, 3131\u20133141 (2018).","journal-title":"ACS Chem. Biol."},{"key":"1598_CR115","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1039\/C7CC03879H","volume":"53","author":"CM Robb","year":"2017","unstructured":"Robb, C. M. et al. Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chem. Commun. 53, 7577\u20137580 (2017).","journal-title":"Chem. Commun."},{"key":"1598_CR116","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s00044-019-02485-4","volume":"29","author":"Y Da","year":"2020","unstructured":"Da, Y. et al. Design, synthesis, and biological evaluation of small molecule PROTACs for potential anticancer effects. Med. Chem. Res. 29, 334\u2013340 (2020).","journal-title":"Med. Chem. Res."},{"key":"1598_CR117","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1021\/acs.jmedchem.0c02234","volume":"64","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. Design and synthesis of EZH2-based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2. J. Med. Chem. 64, 2829\u20132848 (2021).","journal-title":"J. Med. Chem."},{"key":"1598_CR118","doi-asserted-by":"publisher","first-page":"117237","DOI":"10.1016\/j.bmc.2023.117237","volume":"82","author":"W Cheng","year":"2023","unstructured":"Cheng, W. et al. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands. Bioorg. Med. Chem. 82, 117237 (2023).","journal-title":"Bioorg. Med. Chem."},{"key":"1598_CR119","doi-asserted-by":"publisher","first-page":"115974","DOI":"10.1016\/j.ejmech.2023.115974","volume":"264","author":"W Liu","year":"2024","unstructured":"Liu, W. et al. Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia. Eur. J. Med. Chem. 264, 115974 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR120","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.chembiol.2018.11.006","volume":"26","author":"M Brand","year":"2019","unstructured":"Brand, M. et al. Homolog-selective degradation as a strategy to probe the function of CDK6 in AML. Cell Chem. Biol. 26, 300\u2013306.e9 (2019).","journal-title":"Cell Chem. Biol."},{"key":"1598_CR121","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1182\/blood.2019003604","volume":"135","author":"M De Dominici","year":"2020","unstructured":"De Dominici, M. et al. Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs. Blood 135, 1560\u20131573 (2020).","journal-title":"Blood"},{"key":"1598_CR122","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter, G. E. et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science (80) 348, 1376\u20131381 (2015).","journal-title":"Science (80)"},{"key":"1598_CR123","doi-asserted-by":"crossref","unstructured":"Lohbeck, J. & Miller, A. K. Practical synthesis of a phthalimide-based Cereblon ligand to enable PROTAC development. Bioorg. Med. Chem. Lett. 26, 5260\u20135262 (2016). This article details the practical synthesis of a phthalimide-based cereblon ligand, facilitating PROTAC development.","DOI":"10.1016\/j.bmcl.2016.09.048"},{"key":"1598_CR124","doi-asserted-by":"publisher","first-page":"107801","DOI":"10.1016\/j.bioorg.2024.107801","volume":"153","author":"S Wang","year":"2024","unstructured":"Wang, S. et al. Discovery of novel 20S proteasome subunit \u03b25 PROTAC degraders as potential therapeutics for pharyngeal carcinoma and Bortezomib-resistant multiple myeloma. Bioorg. Chem. 153, 107801 (2024).","journal-title":"Bioorg. Chem."},{"key":"1598_CR125","doi-asserted-by":"publisher","first-page":"7575","DOI":"10.1021\/acs.jmedchem.9b00871","volume":"62","author":"S Su","year":"2019","unstructured":"Su, S. et al. Potent and preferential degradation of CDK6 via proteolysis targeting chimera degraders. J. Med. Chem. 62, 7575\u20137582 (2019).","journal-title":"J. Med. Chem."},{"key":"1598_CR126","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.bmc.2009.12.001","volume":"18","author":"SG Stewart","year":"2010","unstructured":"Stewart, S. G. et al. New thalidomide analogues derived through Sonogashira or Suzuki reactions and their TNF expression inhibition profiles. Bioorg. Med. Chem. 18, 650\u2013662 (2010).","journal-title":"Bioorg. Med. Chem."},{"key":"1598_CR127","doi-asserted-by":"publisher","first-page":"104833","DOI":"10.1016\/j.bioorg.2021.104833","volume":"111","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC). Bioorg. Chem. 111, 104833 (2021).","journal-title":"Bioorg. Chem."},{"key":"1598_CR128","doi-asserted-by":"publisher","first-page":"129838","DOI":"10.1016\/j.bmcl.2024.129838","volume":"109","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities. Bioorg. Med. Chem. Lett. 109, 129838 (2024).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1598_CR129","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/cbic.202300482","volume":"24","author":"CM Almod\u00f3var\u2010Rivera","year":"2023","unstructured":"Almod\u00f3var\u2010Rivera, C. M. et al. A modular chemistry platform for the development of a cereblon E3 ligase\u2010based partial PROTAC library. ChemBioChem 24, 4\u20138 (2023).","journal-title":"ChemBioChem"},{"key":"1598_CR130","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.bmcl.2010.12.031","volume":"21","author":"C Chaulet","year":"2011","unstructured":"Chaulet, C. et al. Design, synthesis and biological evaluation of new thalidomide analogues as TNF-\u03b1 and IL-6 production inhibitors. Bioorg. Med. Chem. Lett. 21, 1019\u20131022 (2011).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1598_CR131","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10593-015-1670-0","volume":"51","author":"Y Ponomaryov","year":"2015","unstructured":"Ponomaryov, Y. et al. Scalable and green process for the synthesis of anticancer drug lenalidomide. Chem. Heterocycl. Compd. 51, 133\u2013138 (2015).","journal-title":"Chem. Heterocycl. Compd."},{"key":"1598_CR132","doi-asserted-by":"publisher","first-page":"103817","DOI":"10.1016\/j.bioorg.2020.103817","volume":"99","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative. Bioorg. Chem. 99, 103817 (2020).","journal-title":"Bioorg. Chem."},{"key":"1598_CR133","doi-asserted-by":"crossref","unstructured":"Jin, Y.-H. et al. Azo-PROTAC: novel light-controlled small-molecule tool for protein knockdown. J. Med. Chem. 63, 4644\u20134654 (2020). Introduces Azo-PROTAC, a novel light-controlled small-molecule tool for protein knockdown. It offers a unique approach to spatially and temporally regulate protein degradation, advancing targeted therapeutic strategies.","DOI":"10.1021\/acs.jmedchem.9b02058"},{"key":"1598_CR134","doi-asserted-by":"publisher","first-page":"113435","DOI":"10.1016\/j.ejmech.2021.113435","volume":"219","author":"PD Fischer","year":"2021","unstructured":"Fischer, P. D. et al. A biphenyl inhibitor of eIF4E targeting an internal binding site enables the design of cell-permeable PROTAC-degraders. Eur. J. Med. Chem. 219, 113435 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR135","doi-asserted-by":"publisher","first-page":"113328","DOI":"10.1016\/j.ejmech.2021.113328","volume":"218","author":"X Qu","year":"2021","unstructured":"Qu, X. et al. Effective degradation of EGFRL858R\u2009+\u2009T790M mutant proteins by CRBN-based PROTACs through both proteosome and autophagy\/lysosome degradation systems. Eur. J. Med. Chem. 218, 113328 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR136","doi-asserted-by":"publisher","first-page":"113335","DOI":"10.1016\/j.ejmech.2021.113335","volume":"217","author":"C Ren","year":"2021","unstructured":"Ren, C. et al. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib. Eur. J. Med. Chem. 217, 113335 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR137","doi-asserted-by":"publisher","first-page":"7283","DOI":"10.1021\/acs.jmedchem.4c00107","volume":"67","author":"Y Zhu","year":"2024","unstructured":"Zhu, Y. et al. Design, synthesis, and biological evaluation of novel EGFR PROTACs targeting C797S mutation. J. Med. Chem. 67, 7283\u20137300 (2024).","journal-title":"J. Med. Chem."},{"key":"1598_CR138","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. Discovery of selective and potent ATR degrader for exploration its kinase\u2010independent functions in acute myeloid leukemia cells. Angew. Chemie Int. Ed. 63, e202318568 (2024).","DOI":"10.1002\/anie.202318568"},{"key":"1598_CR139","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.1021\/acs.jmedchem.3c01765","volume":"67","author":"L Liu","year":"2024","unstructured":"Liu, L. et al. Discovery of LLC0424 as a potent and selective in vivo NSD2 PROTAC degrader. J. Med. Chem. 67, 6938\u20136951 (2024).","journal-title":"J. Med. Chem."},{"key":"1598_CR140","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.1021\/acs.jmedchem.8b00506","volume":"61","author":"C Qin","year":"2018","unstructured":"Qin, C. et al. Discovery of QCA570 as an exceptionally potent and efficacious proteolysis targeting chimera (PROTAC) degrader of the bromodomain and extra-terminal (BET) proteins capable of inducing complete and durable tumor regression. J. Med. Chem. 61, 6685\u20136704 (2018).","journal-title":"J. Med. Chem."},{"key":"1598_CR141","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1158\/0008-5472.CAN-16-2622","volume":"77","author":"L Bai","year":"2017","unstructured":"Bai, L. et al. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res. 77, 2476\u20132487 (2017).","journal-title":"Cancer Res."},{"key":"1598_CR142","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.chembiol.2019.11.014","volume":"27","author":"I You","year":"2020","unstructured":"You, I. et al. Discovery of an AKT degrader with prolonged inhibition of downstream signaling. Cell Chem. Biol. 27, 66\u201373.e7 (2020).","journal-title":"Cell Chem. Biol."},{"key":"1598_CR143","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ejmech.2019.05.046","volume":"176","author":"B Wang","year":"2019","unstructured":"Wang, B. et al. Development of selective small molecule MDM2 degraders based on nutlin. Eur. J. Med. Chem. 176, 476\u2013491 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR144","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1021\/acs.jmedchem.8b00909","volume":"62","author":"Y Li","year":"2019","unstructured":"Li, Y. et al. Discovery of MD-224 as a first-in-class, highly potent, and efficacious proteolysis targeting chimera murine double minute 2 degrader capable of achieving complete and durable tumor regression. J. Med. Chem. 62, 448\u2013466 (2019).","journal-title":"J. Med. Chem."},{"key":"1598_CR145","doi-asserted-by":"publisher","first-page":"113425","DOI":"10.1016\/j.ejmech.2021.113425","volume":"219","author":"B Wang","year":"2021","unstructured":"Wang, B. et al. Development of MDM2 degraders based on ligands derived from Ugi reactions: lessons and discoveries. Eur. J. Med. Chem. 219, 113425 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR146","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1021\/acs.jmedchem.0c00339","volume":"63","author":"M-X Li","year":"2020","unstructured":"Li, M.-X. et al. Degradation versus inhibition: development of proteolysis-targeting chimeras for overcoming statin-induced compensatory upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Med. Chem. 63, 4908\u20134928 (2020).","journal-title":"J. Med. Chem."},{"key":"1598_CR147","doi-asserted-by":"crossref","unstructured":"Xiao, D. et al. Design and synthesis of new lenalidomide analogs via Suzuki cross\u2010coupling reaction. Arch. Pharm. (Weinheim). 353, (2020). This article explores the design and synthesis of novel lenalidomide derivatives through the Suzuki cross-coupling reaction.","DOI":"10.1002\/ardp.201900376"},{"key":"1598_CR148","doi-asserted-by":"publisher","first-page":"116972","DOI":"10.1016\/j.biopha.2024.116972","volume":"177","author":"W Chen","year":"2024","unstructured":"Chen, W. et al. CDK9 targeting PROTAC L055 inhibits ER\u03b1-positive breast cancer. Biomed. Pharmacother. 177, 116972 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"1598_CR149","doi-asserted-by":"publisher","first-page":"107924","DOI":"10.1016\/j.cclet.2022.107924","volume":"34","author":"Y Sun","year":"2023","unstructured":"Sun, Y. et al. Developing potent BTKC481S PROTACs for ibrutinib-resistant malignant lymphoma. Chin. Chem. Lett. 34, 107924 (2023).","journal-title":"Chin. Chem. Lett."},{"key":"1598_CR150","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1021\/acs.jmedchem.2c01665","volume":"66","author":"A Kaneshige","year":"2023","unstructured":"Kaneshige, A. et al. Discovery of a potent and selective STAT5 PROTAC degrader with strong antitumor activity in vivo in acute myeloid leukemia. J. Med. Chem. 66, 2717\u20132743 (2023).","journal-title":"J. Med. Chem."},{"key":"1598_CR151","doi-asserted-by":"crossref","unstructured":"Nie, X. et al. Development of phenyl-substituted isoindolinone- and benzimidazole-type cereblon ligands for targeted protein degradation. ChemBioChem 25, (2024).","DOI":"10.1002\/cbic.202300685"},{"key":"1598_CR152","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/j.1476-5381.1965.tb02053.x","volume":"25","author":"H Schumacher","year":"1965","unstructured":"Schumacher, H., Smith, R. L. & Williams, R. T. The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol. Chemother. 25, 324\u2013337 (1965).","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"1598_CR153","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1476-5381.1965.tb02054.x","volume":"25","author":"H Schumacher","year":"1965","unstructured":"Schumacher, H., Smith, R. L. & Williams, R. T. The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br. J. Pharmacol. Chemother. 25, 338\u2013351 (1965).","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"1598_CR154","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1021\/acs.jmedchem.2c01555","volume":"66","author":"M Li","year":"2023","unstructured":"Li, M., Zhi, Y., Liu, B. & Yao, Q. Advancing strategies for proteolysis-targeting chimera design. J. Med. Chem. 66, 2308\u20132329 (2023).","journal-title":"J. Med. Chem."},{"key":"1598_CR155","doi-asserted-by":"publisher","first-page":"26663","DOI":"10.1002\/anie.202108848","volume":"60","author":"J Min","year":"2021","unstructured":"Min, J. et al. Phenyl\u2010glutarimides: alternative cereblon binders for the design of PROTACs. Angew. Chem. Int. Ed. 60, 26663\u201326670 (2021). Phenyl-glutarimides as alternative cereblon binders for PROTAC design, emphasizing their increased stability compared to traditional ligands, which could improve the efficacy and duration of targeted protein degradation therapies.","journal-title":"Angew. Chem. Int. Ed."},{"key":"1598_CR156","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1021\/acsmedchemlett.2c00436","volume":"14","author":"JA Jarusiewicz","year":"2023","unstructured":"Jarusiewicz, J. A. et al. Phenyl dihydrouracil: an alternative cereblon binder for PROTAC design. ACS Med. Chem. Lett. 14, 141\u2013145 (2023).","journal-title":"ACS Med. Chem. Lett."},{"key":"1598_CR157","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1021\/acs.jmedchem.4c02709","volume":"995973","author":"M Actis","year":"2025","unstructured":"Actis, M. et al. Evaluation of cereblon-directing warheads for the development of orally bioavailable PROTACs. J. Med. Chem. 995973, 3591\u20133611 (2025).","journal-title":"J. Med. Chem."},{"key":"1598_CR158","doi-asserted-by":"publisher","first-page":"10589","DOI":"10.1021\/acs.jmedchem.3c02259","volume":"67","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Discovery of novel proteolysis-targeting chimera molecules as degraders of programmed cell death-ligand 1 for breast cancer therapy. J. Med. Chem. 67, 10589\u201310600 (2024).","journal-title":"J. Med. Chem."},{"key":"1598_CR159","doi-asserted-by":"publisher","first-page":"14513","DOI":"10.1021\/acs.jmedchem.3c00851","volume":"66","author":"C Steinebach","year":"2023","unstructured":"Steinebach, C. et al. Leveraging ligand affinity and properties: discovery of novel benzamide-type cereblon binders for the design of PROTACs. J. Med. Chem. 66, 14513\u201314543 (2023).","journal-title":"J. Med. Chem."},{"key":"1598_CR160","doi-asserted-by":"publisher","first-page":"114990","DOI":"10.1016\/j.ejmech.2022.114990","volume":"246","author":"M Krasavin","year":"2023","unstructured":"Krasavin, M. et al. Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines. Eur. J. Med. Chem. 246, 114990 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR161","doi-asserted-by":"publisher","first-page":"116328","DOI":"10.1016\/j.ejmech.2024.116328","volume":"270","author":"R Shevalev","year":"2024","unstructured":"Shevalev, R. et al. Discovery and characterization of potent spiro-isoxazole-based cereblon ligands with a novel binding mode. Eur. J. Med. Chem. 270, 116328 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR162","doi-asserted-by":"publisher","first-page":"15905","DOI":"10.1002\/anie.202101328","volume":"60","author":"G Du","year":"2021","unstructured":"Du, G. et al. Discovery of a potent degrader for fibroblast growth factor receptor 1\/2. Angew. Chem. Int. Ed. 60, 15905\u201315911 (2021).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1598_CR163","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/cmdc.202000249","volume":"15","author":"S Verma","year":"2020","unstructured":"Verma, S. & Manna, D. Controlling PROTACs with light. ChemMedChem 15, 1258\u20131261 (2020).","journal-title":"ChemMedChem"},{"key":"1598_CR164","doi-asserted-by":"publisher","first-page":"18370","DOI":"10.1021\/jacs.9b06422","volume":"141","author":"G Xue","year":"2019","unstructured":"Xue, G., Wang, K., Zhou, D., Zhong, H. & Pan, Z. Light-induced protein degradation with photocaged PROTACs. J. Am. Chem. Soc. 141, 18370\u201318374 (2019).","journal-title":"J. Am. Chem. Soc."},{"key":"1598_CR165","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1021\/jacs.9b12718","volume":"142","author":"Y Naro","year":"2020","unstructured":"Naro, Y., Darrah, K. & Deiters, A. Optical control of small molecule-induced protein degradation. J. Am. Chem. Soc. 142, 2193\u20132197 (2020).","journal-title":"J. Am. Chem. Soc."},{"key":"1598_CR166","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5","volume":"40","author":"HC Kolb","year":"2001","unstructured":"Kolb, H. C., Finn, M. G. & Sharpless, K. B. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 40, 2004\u20132021 (2001).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1598_CR167","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1039\/D3CB00199G","volume":"5","author":"C Yang","year":"2024","unstructured":"Yang, C., Tripathi, R. & Wang, B. Click chemistry in the development of PROTACs. RSC Chem. Biol. 5, 189\u2013197 (2024). This article discusses the role of click chemistry in the development of PROTACs, highlighting its efficiency in facilitating the synthesis of chimeric molecules.","journal-title":"RSC Chem. Biol."},{"key":"1598_CR168","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1021\/cr0783479","volume":"108","author":"M Meldal","year":"2008","unstructured":"Meldal, M. & Torn\u00f8e, C. W. Cu-catalyzed azide\u2212alkyne cycloaddition. Chem. Rev. 108, 2952\u20133015 (2008).","journal-title":"Chem. Rev."},{"key":"1598_CR169","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1021\/acs.jmedchem.6b01872","volume":"61","author":"M Schiedel","year":"2018","unstructured":"Schiedel, M. et al. Chemically induced degradation of sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals). J. Med. Chem. 61, 482\u2013491 (2018).","journal-title":"J. Med. Chem."},{"key":"1598_CR170","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1021\/acs.jmedchem.6b01781","volume":"61","author":"RP Wurz","year":"2018","unstructured":"Wurz, R. P. et al. A \u201cclick chemistry platform\u201d for the rapid synthesis of bispecific molecules for inducing protein degradation. J. Med. Chem. 61, 453\u2013461 (2018).","journal-title":"J. Med. Chem."},{"key":"1598_CR171","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1039\/D0OB02120B","volume":"19","author":"H Liu","year":"2021","unstructured":"Liu, H. et al. Construction of an IMiD-based azide library as a kit for PROTAC research. Org. Biomol. Chem. 19, 166\u2013170 (2021).","journal-title":"Org. Biomol. Chem."},{"key":"1598_CR172","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1039\/D0CC05395C","volume":"57","author":"TA Bemis","year":"2021","unstructured":"Bemis, T. A., La Clair, J. J. & Burkart, M. D. Traceless Staudinger ligation enabled parallel synthesis of proteolysis targeting chimera linker variants. Chem. Commun. 57, 1026\u20131029 (2021).","journal-title":"Chem. Commun."},{"key":"1598_CR173","doi-asserted-by":"publisher","first-page":"8567","DOI":"10.1021\/acs.jmedchem.0c00967","volume":"63","author":"Y Yang","year":"2020","unstructured":"Yang, Y. et al. Global PROTAC toolbox for degrading BCR\u2013ABL overcomes drug-resistant mutants and adverse effects. J. Med. Chem. 63, 8567\u20138583 (2020).","journal-title":"J. Med. Chem."},{"key":"1598_CR174","doi-asserted-by":"crossref","unstructured":"Pasieka, A., Diamanti, E., Uliassi, E. & Laura Bolognesi, M. Click chemistry and targeted degradation: a winning combination for medicinal chemists? ChemMedChem 18, (2023).","DOI":"10.1002\/cmdc.202300422"},{"key":"1598_CR175","doi-asserted-by":"publisher","first-page":"112949","DOI":"10.1016\/j.ejmech.2020.112949","volume":"210","author":"X Jiang","year":"2021","unstructured":"Jiang, X. et al. PROTACs suppression of GSK-3\u03b2, a crucial kinase in neurodegenerative diseases. Eur. J. Med. Chem. 210, 112949 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR176","doi-asserted-by":"publisher","first-page":"107762","DOI":"10.1016\/j.cclet.2022.107762","volume":"34","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Design, synthesis, and evaluation of PD-L1 degraders to enhance T cell killing activity against melanoma. Chin. Chem. Lett. 34, 107762 (2023).","journal-title":"Chin. Chem. Lett."},{"key":"1598_CR177","doi-asserted-by":"crossref","unstructured":"Arndt, C. M. et al. One-pot synthesis of cereblon proteolysis targeting chimeras via photoinduced C(sp2)-C(sp3) cross coupling and amide formation for proteolysis targeting chimera library synthesis. J. Med. Chem. 66, 16939\u201316952 (2023). The use of one-pot synthesis approach for cereblon-targeting PROTACs, utilizing photoinduced cross-coupling and amide formation. This method streamlines the synthesis process, allowing for the efficient generation of diverse degraders.","DOI":"10.1021\/acs.jmedchem.3c01613"},{"key":"1598_CR178","doi-asserted-by":"publisher","first-page":"15282","DOI":"10.1021\/acs.jmedchem.2c01218","volume":"65","author":"IP Bhela","year":"2022","unstructured":"Bhela, I. P. et al. A versatile and sustainable multicomponent platform for the synthesis of protein degraders: proof-of-concept application to BRD4-degrading PROTACs. J. Med. Chem. 65, 15282\u201315299 (2022). A versatile, sustainable multicomponent platform for synthesizing protein degraders, streamlining the process and showcasing its application in BRD4-degrading PROTACs.","journal-title":"J. Med. Chem."},{"key":"1598_CR179","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1021\/ja00897a025","volume":"85","author":"RB Merrifield","year":"1963","unstructured":"Merrifield, R. B. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J. Am. Chem. Soc. 85, 2149\u20132154 (1963).","journal-title":"J. Am. Chem. Soc."},{"key":"1598_CR180","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1021\/acscombsci.8b00044","volume":"20","author":"A Abdildinova","year":"2018","unstructured":"Abdildinova, A. & Gong, Y.-D. Current parallel solid-phase synthesis of drug-like oxadiazole and thiadiazole derivatives for combinatorial chemistry. ACS Comb. Sci. 20, 309\u2013329 (2018). The paper highlights the advantages of solid-phase methods in enabling efficient, scalable, and rapid production of PROTACs, streamlining the synthesis process for drug discovery.","journal-title":"ACS Comb. Sci."},{"key":"1598_CR181","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1039\/C8CC08716D","volume":"55","author":"S Krajcovicova","year":"2019","unstructured":"Krajcovicova, S., Jorda, R., Hendrychova, D., Krystof, V. & Soural, M. Solid-phase synthesis for thalidomide-based proteolysis-targeting chimeras (PROTAC). Chem. Commun. 55, 929\u2013932 (2019).","journal-title":"Chem. Commun."},{"key":"1598_CR182","doi-asserted-by":"crossref","unstructured":"Xu, H. et al. Development of rapid and facile solid\u2010phase synthesis of PROTACs via a variety of binding styles. ChemistryOpen 11, (2022).","DOI":"10.1002\/open.202200131"},{"key":"1598_CR183","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1039\/D3CS01127E","volume":"53","author":"R Stevens","year":"2024","unstructured":"Stevens, R. et al. Innovative, combinatorial and high-throughput approaches to degrader synthesis. Chem. Soc. Rev. 53, 4838\u20134861 (2024). Innovative, combinatorial, and high-throughput approaches to degrader synthesis, focusing on strategies that enhance the efficiency and scalability of producing diverse PROTACs.","journal-title":"Chem. Soc. Rev."},{"key":"1598_CR184","doi-asserted-by":"publisher","first-page":"12098","DOI":"10.1039\/D1SC03551G","volume":"12","author":"RP Thomas","year":"2021","unstructured":"Thomas, R. P. et al. A direct-to-biology high-throughput chemistry approach to reactive fragment screening. Chem. Sci. 12, 12098\u201312106 (2021).","journal-title":"Chem. Sci."},{"key":"1598_CR185","doi-asserted-by":"publisher","first-page":"114317","DOI":"10.1016\/j.ejmech.2022.114317","volume":"236","author":"L Guo","year":"2022","unstructured":"Guo, L. et al. A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions. Eur. J. Med. Chem. 236, 114317 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR186","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1021\/acsmedchemlett.2c00124","volume":"13","author":"CE Hendrick","year":"2022","unstructured":"Hendrick, C. E. et al. Direct-to-biology accelerates PROTAC synthesis and the evaluation of linker effects on permeability and degradation. ACS Med. Chem. Lett. 13, 1182\u20131190 (2022).","journal-title":"ACS Med. Chem. Lett."},{"key":"1598_CR187","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1021\/acsmedchemlett.3c00314","volume":"14","author":"MP Plesniak","year":"2023","unstructured":"Plesniak, M. P. et al. Rapid PROTAC discovery platform: nanomole-scale array synthesis and direct screening of reaction mixtures. ACS Med. Chem. Lett. 14, 1882\u20131890 (2023).","journal-title":"ACS Med. Chem. Lett."},{"key":"1598_CR188","doi-asserted-by":"publisher","first-page":"15437","DOI":"10.1021\/acs.jmedchem.3c01604","volume":"66","author":"R Stevens","year":"2023","unstructured":"Stevens, R. et al. Integrated direct-to-biology platform for the nanoscale synthesis and biological evaluation of PROTACs. J. Med. Chem. 66, 15437\u201315452 (2023).","journal-title":"J. Med. Chem."},{"key":"1598_CR189","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1074\/jbc.M117.816868","volume":"293","author":"AA Akuffo","year":"2018","unstructured":"Akuffo, A. A. et al. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. J. Biol. Chem. 293, 6187\u20136200 (2018).","journal-title":"J. Biol. Chem."},{"key":"1598_CR190","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1007\/s13238-018-0602-z","volume":"10","author":"Z An","year":"2019","unstructured":"An, Z., Lv, W., Su, S., Wu, W. & Rao, Y. Developing potent PROTACs tools for selective degradation of HDAC6 protein. Protein Cell 10, 606\u2013609 (2019).","journal-title":"Protein Cell"},{"key":"1598_CR191","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/cmdc.201800271","volume":"13","author":"GM Burslem","year":"2018","unstructured":"Burslem, G. M. et al. Efficient synthesis of immunomodulatory drug analogues enables exploration of structure\u2013degradation relationships. ChemMedChem 13, 1508\u20131512 (2018).","journal-title":"ChemMedChem"},{"key":"1598_CR192","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bjh.12622","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi, A. K. et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br. J. Haematol. 164, 233\u2013244 (2014).","journal-title":"Br. J. Haematol."},{"key":"1598_CR193","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","volume":"128","author":"KM Kort\u00fcm","year":"2016","unstructured":"Kort\u00fcm, K. M. et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood 128, 1226\u20131233 (2016).","journal-title":"Blood"},{"key":"1598_CR194","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1182\/blood.2020007081","volume":"137","author":"S Gooding","year":"2021","unstructured":"Gooding, S. et al. Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma. Blood 137, 232\u2013237 (2021).","journal-title":"Blood"},{"key":"1598_CR195","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","volume":"18","author":"L Zhang","year":"2019","unstructured":"Zhang, L., Riley-Gillis, B., Vijay, P. & Shen, Y. Acquired resistance to BET-PROTACs (proteolysis-targeting chimeras) caused by genomic alterations in core components of E3 ligase complexes. Mol. Cancer Ther. 18, 1302\u20131311 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"1598_CR196","doi-asserted-by":"publisher","unstructured":"Ottis, P. et al. Cellular resistance mechanisms to targeted protein degradation converge toward impairment of the engaged ubiquitin transfer pathway. ACS Chem. Biol. acschembio. 9b00525https:\/\/doi.org\/10.1021\/acschembio.9b00525 (2019).","DOI":"10.1021\/acschembio.9b00525"},{"key":"1598_CR197","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.leukres.2013.08.015","volume":"38","author":"SR Schuster","year":"2014","unstructured":"Schuster, S. R. et al. The clinical significance of cereblon expression in multiple myeloma. Leuk. Res. 38, 23\u201328 (2014).","journal-title":"Leuk. Res."},{"key":"1598_CR198","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood-2012-06-438101","volume":"121","author":"A Broyl","year":"2013","unstructured":"Broyl, A. et al. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 121, 624\u2013627 (2013).","journal-title":"Blood"},{"key":"1598_CR199","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/bjh.12338","volume":"161","author":"D Heintel","year":"2013","unstructured":"Heintel, D. et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br. J. Haematol. 161, 695\u2013700 (2013).","journal-title":"Br. J. Haematol."},{"key":"1598_CR200","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"YX Zhu","year":"2011","unstructured":"Zhu, Y. X. et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118, 4771\u20134779 (2011).","journal-title":"Blood"},{"key":"1598_CR201","doi-asserted-by":"crossref","unstructured":"Kurimchak, A. M. et al. The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. Sci. Signal. 15, (2022).","DOI":"10.1126\/scisignal.abn2707"},{"key":"1598_CR202","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1021\/acs.biochem.2c00245","volume":"62","author":"JM Sasso","year":"2023","unstructured":"Sasso, J. M. et al. Molecular glues: the adhesive connecting targeted protein degradation to the clinic. Biochemistry 62, 601\u2013623 (2023).","journal-title":"Biochemistry"},{"key":"1598_CR203","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.chembiol.2024.04.001","volume":"31","author":"SA Robinson","year":"2024","unstructured":"Robinson, S. A., Co, J. A. & Banik, S. M. Molecular glues and induced proximity: an evolution of tools and discovery. Cell Chem. Biol. 31, 1089\u20131100 (2024).","journal-title":"Cell Chem. Biol."},{"key":"1598_CR204","doi-asserted-by":"publisher","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","volume":"64","author":"G Dong","year":"2021","unstructured":"Dong, G., Ding, Y., He, S. & Sheng, C. Molecular glues for targeted protein degradation: from serendipity to rational discovery. J. Med. Chem. 64, 10606\u201310620 (2021).","journal-title":"J. Med. Chem."},{"key":"1598_CR205","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.tibs.2024.12.006","volume":"50","author":"Y Liu","year":"2025","unstructured":"Liu, Y., Bai, J., Li, D. & Cang, Y. Routes to molecular glue degrader discovery. Trends Biochem. Sci. 50, 134\u2013142 (2025).","journal-title":"Trends Biochem. Sci."},{"key":"1598_CR206","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ddtec.2019.02.004","volume":"31","author":"PP Chamberlain","year":"2019","unstructured":"Chamberlain, P. P. & Cathers, B. E. Cereblon modulators: low molecular weight inducers of protein degradation. Drug Discov. Today Technol. 31, 29\u201334 (2019).","journal-title":"Drug Discov. Today Technol."},{"key":"1598_CR207","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nsmb.2874","volume":"21","author":"PP Chamberlain","year":"2014","unstructured":"Chamberlain, P. P. et al. Structure of the human Cereblon\u2013DDB1\u2013lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat. Struct. Mol. Biol. 21, 803\u2013809 (2014).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1598_CR208","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature14610","volume":"523","author":"J Kr\u00f6nke","year":"2015","unstructured":"Kr\u00f6nke, J. et al. Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del(5q) MDS. Nature 523, 183\u2013188 (2015).","journal-title":"Nature"},{"key":"1598_CR209","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41589-020-0645-3","volume":"16","author":"J Yamamoto","year":"2020","unstructured":"Yamamoto, J. et al. ARID2 is a pomalidomide-dependent CRL4CRBN substrate in multiple myeloma cells. Nat. Chem. Biol. 16, 1208\u20131217 (2020).","journal-title":"Nat. Chem. Biol."},{"key":"1598_CR210","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase. Nature 535, 252\u2013257 (2016).","journal-title":"Nature"},{"key":"1598_CR211","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","volume":"34","author":"CC Bjorklund","year":"2020","unstructured":"Bjorklund, C. C. et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia 34, 1197\u20131201 (2020).","journal-title":"Leukemia"},{"key":"1598_CR212","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","volume":"61","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela, M. E. et al. A cereblon modulator (CC-220) with improved degradation of ikaros and aiolos. J. Med. Chem. 61, 535\u2013542 (2018).","journal-title":"J. Med. Chem."},{"key":"1598_CR213","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jaad.2024.09.074","volume":"92","author":"VP Werth","year":"2025","unstructured":"Werth, V. P. et al. Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial. J. Am. Acad. Dermatol. 92, 435\u2013443 (2025).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1598_CR214","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","volume":"389","author":"PG Richardson","year":"2023","unstructured":"Richardson, P. G. et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N. Engl. J. Med. 389, 1009\u20131022 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1598_CR215","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","volume":"63","author":"JD Hansen","year":"2020","unstructured":"Hansen, J. D. et al. Discovery of CRBN E3 ligase modulator CC-92480 for the treatment of relapsed and refractory multiple myeloma. J. Med. Chem. 63, 6648\u20136676 (2020).","journal-title":"J. Med. Chem."},{"key":"1598_CR216","unstructured":"Arvinas. Vepdegestrant: a PROTAC Estrogen Receptor Degrader for Breast Cancer. https:\/\/www.arvinas.com\/research-and-development\/estrogen-receptor\/."},{"key":"1598_CR217","unstructured":"Pfizer. Arvinas and Pfizer Announce PROTAC\u00ae Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER\u2009+\u2009\/HER2- Breast Cancer | Pfizer. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/arvinas-and-pfizer-announce-protacr-protein-degrader-arv?utm_source=chatgpt.com (2021)."},{"key":"1598_CR218","unstructured":"Arvinas. Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC) | Arvinas. https:\/\/ir.arvinas.com\/news-releases\/news-release-details\/arvinas-announces-arv-471-achieves-clinical-benefit-rate-38?utm_source=chatgpt.com (2022)."},{"key":"1598_CR219","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/d41573-021-00052-4","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard, A. Targeted protein degraders crowd into the clinic. Nat. Rev. Drug Discov. 20, 247\u2013250 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1598_CR220","doi-asserted-by":"publisher","first-page":"TPS290","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS290","volume":"41","author":"DP Petrylak","year":"2023","unstructured":"Petrylak, D. P. et al. A phase 2 expansion study of ARV-766, a PROTACandrogen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 41, TPS290 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1598_CR221","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1200\/JCO.2024.42.16_suppl.5011","volume":"42","author":"DP Petrylak","year":"2024","unstructured":"Petrylak, D. P. et al. ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1\/2 study. J. Clin. Oncol. 42, 5011 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1598_CR222","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","volume":"36","author":"DE Rathkopf","year":"2025","unstructured":"Rathkopf, D. E. et al. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann. Oncol. 36, 76\u201388 (2025).","journal-title":"Ann. Oncol."},{"key":"1598_CR223","doi-asserted-by":"publisher","first-page":"115793","DOI":"10.1016\/j.ejmech.2023.115793","volume":"261","author":"S Zeng","year":"2023","unstructured":"Zeng, S. et al. Current advances and development strategies of orally bioavailable PROTACs. Eur. J. Med. Chem. 261, 115793 (2023).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR224","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1124\/dmd.122.001154","volume":"51","author":"LP Volak","year":"2023","unstructured":"Volak, L. P. et al. Industry perspective on the pharmacokinetic and absorption, distribution, metabolism, and excretion characterization of heterobifunctional protein degraders. Drug Metab. Dispos. 51, 792\u2013803 (2023).","journal-title":"Drug Metab. Dispos."},{"key":"1598_CR225","doi-asserted-by":"publisher","first-page":"116520","DOI":"10.1016\/j.ejmech.2024.116520","volume":"273","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Application and challenges of nitrogen heterocycles in PROTAC linker. Eur. J. Med. Chem. 273, 116520 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR226","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.drudis.2020.07.013","volume":"25","author":"A Pike","year":"2020","unstructured":"Pike, A., Williamson, B., Harlfinger, S., Martin, S. & McGinnity, D. F. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. Drug Discov. Today 25, 1793\u20131800 (2020).","journal-title":"Drug Discov. Today"},{"key":"1598_CR227","doi-asserted-by":"publisher","first-page":"103917","DOI":"10.1016\/j.drudis.2024.103917","volume":"29","author":"G Apprato","year":"2024","unstructured":"Apprato, G. et al. Exploring the chemical space of orally bioavailable PROTACs. Drug Discov. Today 29, 103917 (2024).","journal-title":"Drug Discov. Today"},{"key":"1598_CR228","doi-asserted-by":"publisher","first-page":"116789","DOI":"10.1016\/j.ejmech.2024.116789","volume":"277","author":"D Mi","year":"2024","unstructured":"Mi, D. et al. Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo. Eur. J. Med. Chem. 277, 116789 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR229","doi-asserted-by":"publisher","first-page":"6952","DOI":"10.1021\/acs.jmedchem.3c02195","volume":"67","author":"J Hu","year":"2024","unstructured":"Hu, J. et al. Discovery of highly potent and efficient CBP\/p300 degraders with strong in vivo antitumor activity. J. Med. Chem. 67, 6952\u20136986 (2024).","journal-title":"J. Med. Chem."},{"key":"1598_CR230","doi-asserted-by":"publisher","first-page":"13879","DOI":"10.1039\/D4CC05138F","volume":"60","author":"AR Pavan","year":"2024","unstructured":"Pavan, A. R. et al. Cereblon-recruiting proteolysis targeting chimeras (PROTACs) can determine the selective degradation of HDAC1 over HDAC3. Chem. Commun. 60, 13879\u201313882 (2024).","journal-title":"Chem. Commun."},{"key":"1598_CR231","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.chembiol.2019.12.006","volume":"27","author":"M Zeng","year":"2020","unstructured":"Zeng, M. et al. Exploring targeted degradation strategy for oncogenic KRASG12C. Cell Chem. Biol. 27, e6 (2020).","journal-title":"Cell Chem. Biol."},{"key":"1598_CR232","doi-asserted-by":"publisher","first-page":"117381","DOI":"10.1016\/j.ejmech.2025.117381","volume":"288","author":"Y Xu","year":"2025","unstructured":"Xu, Y. et al. Discovery of highly potent dual GSPT1\/BRD4 degraders with anti-AML activity. Eur. J. Med. Chem. 288, 117381 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"1598_CR233","unstructured":"ClinicalTrials.gov. A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. https:\/\/clinicaltrials.gov\/study\/NCT05654623?term=NCT05654623&rank=1."},{"key":"1598_CR234","unstructured":"ClinicalTrials.gov. A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator\u2019s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer. https:\/\/clinicaltrials.gov\/study\/NCT06764485?term=NCT06764485&rank=1."},{"key":"1598_CR235","unstructured":"ClinicalTrials.gov. Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer. https:\/\/clinicaltrials.gov\/study\/NCT04428788?term=NCT04428788&rank=1."},{"key":"1598_CR236","unstructured":"ClinicalTrials.gov. Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis. https:\/\/clinicaltrials.gov\/study\/NCT06058156?term=NCT06058156&rank=1."},{"key":"1598_CR237","unstructured":"ClinicalTrials.gov. A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa. https:\/\/clinicaltrials.gov\/study\/NCT06028230?term=NCT06028230&rank=1."},{"key":"1598_CR238","unstructured":"ClinicalTrials.gov. Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer. https:\/\/clinicaltrials.gov\/study\/NCT03888612?term=NCT03888612&rank=1."},{"key":"1598_CR239","unstructured":"ClinicalTrials.gov. Study details | A study of ARV-766 given by mouth in men with metastatic Prostate Cancer | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05067140?term=NCT05067140&rank=1."},{"key":"1598_CR240","unstructured":"ClinicalTrials.gov. A study to characterize the safety, tolerability, and preliminary efficacy of CFT1946 as monotherapy and combination therapy in subjects with BRAF V600 mutant solid tumors. https:\/\/clinicaltrials.gov\/study\/NCT05668585?term=NCT05668585&rank=1."},{"key":"1598_CR241","unstructured":"ClinicalTrials.gov. A study to assess the safety and tolerability of CFT8634 in locally advanced or metastatic SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-Null tumors. https:\/\/clinicaltrials.gov\/study\/NCT05355753?term=NCT05355753&rank=1."},{"key":"1598_CR242","unstructured":"ClinicalTrials.gov. Study details | A dose-escalation and expansion study of BGB-16673 in participants with B-cell malignancies | ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05006716?term=NCT05006716&rank=1."},{"key":"1598_CR243","unstructured":"ClinicalTrials.gov. Treatment of Chinese participants with B-cell malignancies with BGB-16673, a Bruton tyrosine kinase-targeted protein-degrader. https:\/\/clinicaltrials.gov\/study\/NCT05294731?term=NCT05294731&rank=1."},{"key":"1598_CR244","unstructured":"ClinicalTrials.gov. A study to investigate safety and effectiveness of BGB-16673 in combination with other agents in participants with relapsed or refractory B-cell malignancies. https:\/\/clinicaltrials.gov\/study\/NCT06634589?term=NCT06634589&rank=1."},{"key":"1598_CR245","unstructured":"ClinicalTrials.gov. A study of NX-2127 in adults with relapsed\/refractory B-cell malignancies. https:\/\/clinicaltrials.gov\/study\/NCT04830137?term=NCT04830137&rank=1."},{"key":"1598_CR246","unstructured":"ClinicalTrials.gov. FHD-609 in subjects with advanced synovial sarcoma or advanced SMARCB1-loss tumors. https:\/\/clinicaltrials.gov\/study\/NCT04965753?term=NCT04965753&rank=1."},{"key":"1598_CR247","unstructured":"ClinicalTrials.gov. Safety, PK\/PD, and clinical activity of KT-413 in adult patients with relapsed or refractory B-cell NHL. https:\/\/clinicaltrials.gov\/study\/NCT05233033?term=NCT05233033&rank=1."},{"key":"1598_CR248","unstructured":"ClinicalTrials.gov. A study of NX-5948 in adults with relapsed\/refractory B-cell malignancies. https:\/\/clinicaltrials.gov\/study\/NCT05131022?term=NCT05131022&rank=1."},{"key":"1598_CR249","unstructured":"ClinicalTrials.gov. A study to assess BMS-986458 alone and in combination with anti-lymphoma agents in relapsed\/refractory non-Hodgkin lymphomas. https:\/\/clinicaltrials.gov\/study\/NCT06090539?term=NCT06090539&rank=1."},{"key":"1598_CR250","unstructured":"ClinicalTrials.gov. A study of AC682 for the treatment of locally advanced or metastatic ER+ breast cancer. https:\/\/clinicaltrials.gov\/study\/NCT05080842?term=NCT05080842&rank=1."},{"key":"1598_CR251","unstructured":"ClinicalTrials.gov. A study of AC676 for the treatment of relapsed\/refractory B-Cell malignancies. https:\/\/clinicaltrials.gov\/study\/NCT05780034?term=NCT05780034&rank=1."},{"key":"1598_CR252","unstructured":"ClinicalTrials.gov. A study of HSK29116 in adults with relapsed\/refractory B-cell malignancies. https:\/\/clinicaltrials.gov\/study\/NCT04861779?term=NCT04861779&rank=1."},{"key":"1598_CR253","unstructured":"ClinicalTrials.gov. Study in subjects to evaluate the safety, tolerability and pharmacokinetics of GT20029. https:\/\/clinicaltrials.gov\/study\/NCT05428449?term=NCT05428449&rank=1."},{"key":"1598_CR254","unstructured":"ClinicalTrials.gov. A phase I study to assess the safety, pharmacokinetics, and anti-tumor activity of oral HP518 in mCRPC patients. https:\/\/clinicaltrials.gov\/study\/NCT06155084?term=NCT06155084&rank=1."}],"container-title":["Communications Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01598-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01598-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01598-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T09:03:24Z","timestamp":1757322204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42004-025-01598-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":254,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1598"],"URL":"https:\/\/doi.org\/10.1038\/s42004-025-01598-9","relation":{},"ISSN":["2399-3669"],"issn-type":[{"value":"2399-3669","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"218"}}